Literature DB >> 6984293

Leydig cells nonspecifically suppress lymphoproliferation in vitro: implications for the testis as an immunologically privileged site.

W Born, H Wekerle.   

Abstract

We have studied the influence of mouse testis cells on unstimulated lymphoproliferation; on allogeneic mixed lymphocyte reaction; and on concanavalin A-stimulated, phytohemagglutinin-stimulated, or lipopolysaccaride-stimulated responses in vitro. Co-culture with highly enriched irradiated (2000 R) Leydig cells (LC) led in each case to a considerable reduction of 3H TdR uptake. Prolonged tissue graft survival times suggest that the testis is an immunologically privileged site. This may be explained by an immune-suppressive function of LC in vivo. LC are also capable of selectively binding lymphoid and myeloid cells to their surface. This capacity, accompanied by a suppression of immune reactivity in situ, may play a role in cases of testicular relapse observed in acute leukemia.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6984293     DOI: 10.1111/j.1600-0897.1982.tb00195.x

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 0271-7352            Impact factor:   3.886


  3 in total

1.  Differentiation of mast cells during postnatal development of neonatally estrogen-treated rats.

Authors:  F Gaytan; C Bellido; G Carrera; E Aguilar
Journal:  Cell Tissue Res       Date:  1990-01       Impact factor: 5.249

2.  Testisimmune privilege - Assumptions versus facts.

Authors:  G Kaur; P Mital; J M Dufour
Journal:  Anim Reprod       Date:  2013-01       Impact factor: 1.807

3.  Specific autoantigens identified by sera obtained from mice that are immunized with testicular germ cells alone.

Authors:  Hayato Terayama; Shuichi Hirai; Munekazu Naito; Ning Qu; Chiaki Katagiri; Kenta Nagahori; Shogo Hayashi; Hiraku Sasaki; Shota Moriya; Masaki Hiramoto; Keisuke Miyazawa; Naoyuki Hatayama; Zhong-Lian Li; Kou Sakabe; Masayuki Matsushita; Masahiro Itoh
Journal:  Sci Rep       Date:  2016-10-18       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.